



TORRENT PHARMACEUTICALS LIMITED

Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: +91 79 26599000 Fax: + 91 79 26582100
CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com

(Rs. in crores except per share data)

Statement of Standalone Audited Financial Results for the Quarter ended 30-Jun-2020

Particulars	Quarter ended			Year ended
	30-Jun-2020	31-Mar-2020	30-Jun-2019	31-Mar-2020
Revenue				
Net sales	1685	1457	1566	6026
Other operating income	42	34	37	142
Revenue from operations (net)	1727	1491	1603	6168
Other income	7	21	31	237
Total revenue	1734	1512	1634	6405
Expenses				
Cost of materials consumed	353	326	366	1353
Purchases of stock-in-trade	109	103	69	341
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(28)	(54)	(16)	(57)
Employee benefits expense	288	258	280	1062
Finance costs	97	96	117	430
Depreciation and amortisation expense	150	155	149	607
Other expenses	395	433	392	1552
Total expenses	1364	1317	1357	5288
Profit before tax	370	195	277	1117
Tax expense				
Current Tax	64	34	60	192
Deferred Tax	8	(7)	(6)	(14)
Total tax expense	72	27	54	178
Net profit for the period	298	168	223	939
Other comprehensive income				
Items that will not be reclassified subsequently to profit or loss	(6)	(3)	(3)	(17)
Income tax relating to items that will not be reclassified subsequently to profit or loss	2	1	1	6
Items that will be reclassified subsequently to profit or loss	37	(91)	9	(160)
Income tax relating to items that will be reclassified subsequently to profit or loss	(13)	32	(3)	56
Total other comprehensive income	20	(61)	4	(115)
Total comprehensive income	318	107	227	824
Paid-up equity share capital (Face value of Rs. 5 each)	84.62	84.62	84.62	84.62
Other Equity excluding Revaluation Reserves				5036
Earnings per share (of Rs. 5/- each) (not annualised for the quarter):				
Basic	17.63	9.91	13.18	55.46
Diluted	17.63	9.91	13.18	55.46

Notes:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30-Jul-2020. The auditor have carried out an audit of the above said results. There is no qualification in the auditor's report on this statement of financial results.
- 2 The Company operates in a single segment i.e Generic Formulation Business.
- 3 The figures for the quarter ended 31-Mar-2020 is the balancing figure between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year.
- 4 The listed non-convertible debentures of the company aggregating Rs. 2019 crores as at 30-Jun-2020 (previous year Rs. 1707 crores) are secured by way of first pari passu charge through mortgage on certain specified immovable & movable assets and hypothecation of identified trademarks of the Company and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
- 5 The Company has considered internal and external information while finalizing various estimates and recoverability of assets in relation to its financial statement captions upto the date of approval of the financial results by the Board of Directors. The impact of Covid-19 may be different from what is estimated as at such date of approval of the financial results and the Company will continue to monitor any material changes to future economic conditions.
- 6 The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.

For TORRENT PHARMACEUTICALS LIMITED

**SAMIR
UTTAMLAL
MEHTA** Digitally signed by
SAMIR UTTAMLAL
MEHTA
Date: 2020.07.30
16:32:23 +05'30'

Place : Ahmedabad, Gujarat

Date : 30-Jul-2020

**SAMIR MEHTA
Executive Chairman**